• Je něco špatně v tomto záznamu ?

Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas

J. Bartkova, P. Hamerlik, M. T. Stockhausen, J. Ehrmann, A. Hlobilkova, H. Laursen, O. Kalita, Z. Kolar, H. S. Poulsen, H. Broholm, J. Lukas, J. Bartek

. 2010 ; 29 (36) : 5095-5102.

Jazyk angličtina Země Anglie, Velká Británie

Perzistentní odkaz   https://www.medvik.cz/link/bmc14075887

Grantová podpora
NS10282 MZ0 CEP - Centrální evidence projektů
NT11065 MZ0 CEP - Centrální evidence projektů

Malignant gliomas, the deadliest of brain neoplasms, show rampant genetic instability and resistance to genotoxic therapies, implicating potentially aberrant DNA damage response (DDR) in glioma pathogenesis and treatment failure. Here, we report on gross, aberrant constitutive activation of DNA damage signalling in low- and high-grade human gliomas, and analyze the sources of such endogenous genotoxic stress. Based on analyses of human glioblastoma multiforme (GBM) cell lines, normal astrocytes and clinical specimens from grade II astrocytomas (n=41) and grade IV GBM (n=60), we conclude that the DDR machinery is constitutively activated in gliomas, as documented by phosphorylated histone H2AX (gammaH2AX), activation of the ATM-Chk2-p53 pathway, 53BP1 foci and other markers. Oxidative DNA damage (8-oxoguanine) was high in some GBM cell lines and many GBM tumors, while it was low in normal brain and grade II astrocytomas, despite the degree of DDR activation was higher in grade II tumors. Markers indicative of ongoing DNA replication stress (Chk1 activation, Rad17 phosphorylation, replication protein A foci and single-stranded DNA) were present in GBM cells under high- or low-oxygen culture conditions and in clinical specimens of both low- and high-grade tumors. The observed global checkpoint signaling, in contrast to only focal areas of overabundant p53 (indicative of p53 mutation) in grade II astrocytomas, are consistent with DDR activation being an early event in gliomagenesis, initially limiting cell proliferation (low Ki-67 index) and selecting for mutations of p53 and likely other genes that allow escape (higher Ki-67 index) from the checkpoint and facilitate tumor progression. Overall, these results support the potential role of the DDR machinery as a barrier to gliomagenesis and indicate that replication stress, rather than oxidative stress, fuels the DNA damage signalling in early stages of astrocytoma development.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14075887
003      
CZ-PrNML
005      
20170418094506.0
007      
ta
008      
141016s2010 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/onc.2010.249 $2 doi
035    __
$a (PubMed)20581868
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Bártková, Jiřina $7 xx0094304 $u Institute of Cancer Biology and Centre for Genotoxic Stress Research, Danish Cancer Society, Copenhagen, Denmark
245    10
$a Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas / $c J. Bartkova, P. Hamerlik, M. T. Stockhausen, J. Ehrmann, A. Hlobilkova, H. Laursen, O. Kalita, Z. Kolar, H. S. Poulsen, H. Broholm, J. Lukas, J. Bartek
520    9_
$a Malignant gliomas, the deadliest of brain neoplasms, show rampant genetic instability and resistance to genotoxic therapies, implicating potentially aberrant DNA damage response (DDR) in glioma pathogenesis and treatment failure. Here, we report on gross, aberrant constitutive activation of DNA damage signalling in low- and high-grade human gliomas, and analyze the sources of such endogenous genotoxic stress. Based on analyses of human glioblastoma multiforme (GBM) cell lines, normal astrocytes and clinical specimens from grade II astrocytomas (n=41) and grade IV GBM (n=60), we conclude that the DDR machinery is constitutively activated in gliomas, as documented by phosphorylated histone H2AX (gammaH2AX), activation of the ATM-Chk2-p53 pathway, 53BP1 foci and other markers. Oxidative DNA damage (8-oxoguanine) was high in some GBM cell lines and many GBM tumors, while it was low in normal brain and grade II astrocytomas, despite the degree of DDR activation was higher in grade II tumors. Markers indicative of ongoing DNA replication stress (Chk1 activation, Rad17 phosphorylation, replication protein A foci and single-stranded DNA) were present in GBM cells under high- or low-oxygen culture conditions and in clinical specimens of both low- and high-grade tumors. The observed global checkpoint signaling, in contrast to only focal areas of overabundant p53 (indicative of p53 mutation) in grade II astrocytomas, are consistent with DDR activation being an early event in gliomagenesis, initially limiting cell proliferation (low Ki-67 index) and selecting for mutations of p53 and likely other genes that allow escape (higher Ki-67 index) from the checkpoint and facilitate tumor progression. Overall, these results support the potential role of the DDR machinery as a barrier to gliomagenesis and indicate that replication stress, rather than oxidative stress, fuels the DNA damage signalling in early stages of astrocytoma development.
590    __
$a bohemika - dle Pubmed
650    12
$a nádory mozku $x genetika $7 D001932
650    02
$a nádory mozku $x metabolismus $7 D001932
650    02
$a nádory mozku $x patologie $7 D001932
650    02
$a nádorové buněčné linie $7 D045744
650    12
$a poškození DNA $x fyziologie $7 D004249
650    02
$a replikace DNA $x genetika $7 D004261
650    12
$a replikace DNA $x fyziologie $7 D004261
650    12
$a gliom $x genetika $7 D005910
650    02
$a gliom $x metabolismus $7 D005910
650    02
$a gliom $x patologie $7 D005910
650    02
$a histony $x metabolismus $7 D006657
650    02
$a lidé $7 D006801
650    02
$a antigen Ki-67 $x metabolismus $7 D019394
650    12
$a oxidační stres $x fyziologie $7 D018384
650    02
$a signální transdukce $x genetika $7 D015398
650    12
$a fyziologický stres $x fyziologie $7 D013312
650    02
$a nádorový supresorový protein p53 $x metabolismus $7 D016159
700    1_
$a Hamerlik, P. $u Institute of Cancer Biology and Centre for Genotoxic Stress Research, Danish Cancer Society, Copenhagen, Denmark; Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Palacky University, Olomouc, Czech Republic; Molecular Pathology, Institute of Molecular and Translational Medicine, Palacky University, Olomouc, Czech Republic
700    1_
$a Stockhausen, M. T. $u Department of Radiation Biology, Copenhagen University Hospital, Copenhagen, Denmark
700    1_
$a Ehrmann, Jiří, $u Molecular Pathology, Institute of Molecular and Translational Medicine, Palacky University, Olomouc, Czech Republic $d 1967- $7 jo2003163162
700    1_
$a Hlobilková, Alice, $d 1972- $7 xx0019008 $u Molecular Pathology, Institute of Molecular and Translational Medicine, Palacky University, Olomouc, Czech Republic
700    1_
$a Laursen, H. $u Department of Neuropathology, Copenhagen University Hospital, Copenhagen, Denmark
700    1_
$a Kalita, O. $u Department of Neurosurgery, University Hospital, Olomouc, Czech Republic
700    1_
$a Kolář, Zdeněk, $d 1953- $7 jn20000710256 $u Molecular Pathology, Institute of Molecular and Translational Medicine, Palacky University, Olomouc, Czech Republic
700    1_
$a Poulsen, H.S. $u Department of Radiation Biology, Copenhagen University Hospital, Copenhagen, Denmark
700    1_
$a Broholm, H. $u Department of Neuropathology, Copenhagen University Hospital, Copenhagen, Denmark
700    1_
$a Lukáš, Jiří $7 xx0094305 $u Institute of Cancer Biology and Centre for Genotoxic Stress Research, Danish Cancer Society, Copenhagen, Denmark
700    1_
$a Bártek, Jiří, $d 1953- $7 xx0046271 $u Institute of Cancer Biology and Centre for Genotoxic Stress Research, Danish Cancer Society, Copenhagen, Denmark; Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Palacky University, Olomouc, Czech Republic
773    0_
$t Oncogene $g Roč. 29, č. 36 (2010), s. 5095-5102 $p Oncogene $x 0950-9232 $w MED00003600
773    0_
$p Oncogene $g 29(36):5095-102, 2010 Sep 9
910    __
$a ABA008 $y 4 $z 0
990    __
$a 20141016165317 $b ABA008
991    __
$a 20170418094813 $b ABA008
999    __
$a ok $b bmc $g 1043928 $s 874814
BAS    __
$a 3
BMC    __
$a 2010 $b 29 $c 36 $d 5095-5102 $x MED00003600 $i 0950-9232 $m Oncogene $n Oncogene
GRA    __
$a NS10282 $p MZ0
GRA    __
$a NT11065 $p MZ0
LZP    __
$a NLK 2014-1/lp

Najít záznam

Citační ukazatele

Možnosti archivace